Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by year end 2020 HOUSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
CEO Jay Shepard to step down from his current role after a successor is appointed HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including
AVB-500 demonstrates favorable safety profile and full suppression of circulating GAS6 in cancer patients HOUSTON , July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. ( Aravive ) (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, announced that the independent Data Monitoring Committtee (DMC)
Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline Jay Shepard to Assume Role of Chairman of the Board of Directors HOUSTON , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage
HOUSTON , March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: Event: Cowen and Company 39th Annual Health Care Conference Presentation Date &
HOUSTON , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
HOUSTON , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the
HOUSTON , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference: Event: Piper Jaffray Healthcare Conference Presentation Date & Time: Tuesday,
HOUSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, today announced that company management will participate at the following upcoming investor
